Topic: precancerous tumors

The circulating cell-free tumor DNA market plays a vital role as they provide non-invasive options for cancer diagnosis and prognosis. With advantages such as ease of procurement through blood draws and ability to detect cancer across all stages, demand for circulating cell-free tumor DNA is increasing globally. The Global circulating cell-free tumor DNA Market is estimated to be valued at US$ 7.03 Mn in 2024 and is expected to exhibit a CAGR of 6.4% over the forecast period 2024 to 2030.   ...